Figures
Abstract
Cardiotoxicity is an aggravating side effect of many clinical antineoplastic agents such as arsenic trioxide (As2O3), which is the first-line treatment for acute promyelocytic leukemia (APL). Clinically, drug combination strategies are widely applied for complex disease management. Here, an optimized, cardiac-friendly therapeutic strategy for APL was investigated using a combination of As2O3 and genistein or resveratrol. Potential combinations were explored with respect to their effects on mitochondrial membrane potential, reactive oxygen species, superoxide dismutase activity, autophagy, and apoptosis in both NB4 cells and neonatal rat left ventricular myocytes. All experiments consistently suggested that 5 µM resveratrol remarkably alleviates As2O3-induced cardiotoxicity. To achieve an equivalent effect, a 10-fold dosage of genistein was required, thus highlighting the dose advantage of resveratrol, as poor bioavailability is a common concern for its clinical application. Co-administration of resveratrol substantially amplified the anticancer effect of As2O3 in NB4 cells. Furthermore, resveratrol exacerbated oxidative stress, mitochondrial damage, and apoptosis, thereby reflecting its full range of synergism with As2O3. Addition of 5 µM resveratrol to the single drug formula of As2O3 also further increased the expression of LC3, a marker of cellular autophagy activity, indicating an involvement of autophagy-mediated tumor cell death in the synergistic action. Our results suggest a possible application of an As2O3 and resveratrol combination to treat APL in order to achieve superior therapeutics effects and prevent cardiotoxicity.
Citation: Fan Y, Chen M, Meng J, Yu L, Tu Y, Wan L, et al. (2014) Arsenic Trioxide and Resveratrol Show Synergistic Anti-Leukemia Activity and Neutralized Cardiotoxicity. PLoS ONE 9(8): e105890. https://doi.org/10.1371/journal.pone.0105890
Editor: Pierre Bobé, INSERM-Université Paris-Sud, France
Received: February 24, 2014; Accepted: July 25, 2014; Published: August 21, 2014
Copyright: © 2014 Fan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Natural Science Foundation of China (No. 31301136) and Foundation of Health Department of Heilongjiang Province of China (No. 2011-233). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Due to its substantial anticancer effect, arsenic trioxide (As2O3) has been recommended as the front-line agent for treatment of acute promyelocytic leukemia (APL), particularly for cases of relapsed or refractory APL [1]–[3]. Although generally considered a relatively safe therapeutic strategy [4], numerous clinical reports have indicated that chronic exposure to a therapeutic dose of As2O3 could damage cardiac structure and functions and evoke severe cardiac side effects such as ventricular arrhythmia, even resulting in sudden cardiac death in certain cases [5]–[8]. This issue may become increasingly relevant due to the significantly extended survival time of APL patients, and therefore increased likelihood of long-term exposure to As2O3 resulting in cardiovascular disease. Thus, prophylactic treatment is urgently required for managing the consequent cardiotoxicity in clinical applications of As2O3.
A better understanding of the potential mechanism by which As2O3 induces its cardiotoxicity will undoubtedly be of value for developing specific and effective preventive measures. Recently, many experimental observations have revealed that mitochondrial microstructural changes and dysfunctions might play crucial roles in As2O3-mediated cardiotoxicity via inducing excessive production of reactive oxygen species (ROS), and the subsequent increase in cell apoptosis [9]–[12]. Indeed, enrichment of mitochondriain cardiomyocytes enhanced their susceptibility to oxidative damage compared to other cells [13]. Accordingly, a prophylactic strategy was proposed that is based on maintaining mitochondrial function to guard against As2O3-induced oxidative stress [14]. This suggests that natural, strong antioxidants might be ideal drug candidates. Recently, such antioxidants have been investigated as rational cardioprotectants against the cardiotoxicity induced by As2O3, including the flavonoid genistein (Gen) as well resveratrol (Rev), a stilbene that is enriched in red wine [15], [16]. These investigations have pointed to the use of a combination treatment of Gen or Rev (Gen/Rev) and As2O3 as a novel therapeutic strategy for APL to prevent cardiotoxicity. Nonetheless, many important issues have yet to be considered. First, the exact mechanism regarding the cardioprotective effect of Gen/Rev against As2O3 remains elusive. Second, due to poor bioavailability of polyphenolic compounds, a reasonable and feasible choice of drugs is necessary [17]. Third, the potential antitumor effects of the use of Gen/Rev and As2O3 in combination in APL are unknown. Finally, although previous studies have validated the anticancer effect of Gen and Rev independently [18], [19], it is still unknown whether they can be effective at suppressing the proliferation of APL cancer cells and assist As2O3. This is a particularly important line of evidence that is required to determine whether the proposed new method is superior to the currently widely applied As2O3 monotherapy strategy.
Therefore, in this study, the ability of these two natural antioxidants, Gen and Rev, to reverse As2O3-induced oxidative stress injuries and simultaneously enhance the anticancer effect of As2O3 was investigated in vitro in neonatal rat left ventricular myocytes (NRLVMs) and NB4 cells, respectively. Our experiments focused on drug-induced alterations of mitochondria-derived ROS generation and the secondarily triggered cell apoptosis. Due to an intrinsic functional relationship between the mediators implicated in regulating oxidative stress and autophagy [20], we also measured the protein expression of LC3, a marker of cellular autophagy activity. We designed these experiments with the aim of providing mechanism-based answers to the open questions related to the potential of Gen/Rev plus As2O3 combinatorial therapy for APL.
Materials and Methods
Reagents and drugs
Gen and Rev were provided by Xi’an QingYue Biotechnology Co. Ltd. (China) and Sigma Chemical Co. (St. Louis, MO, USA), respectively. As2O3 was acquired from Harbin YI-DA Pharmaceutical Limited Company. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), cell-penetrating lipophilic cationic fluorochrome JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazole-carbocyanide iodine), the Total Superoxide Dismutase Assay Kit with 2-(4-iodophenyl)- 3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-1), and Annexin V-FITC Apoptosis Detection Kit were bought from Beyotime Institute of Biotechnology (China) and stored at −20°C in the dark. The 2′,7′-dichlorofluorescein diacetate (DCFH-DA) was provided by Molecular Probes (Eugene, OR, USA). The TUNEL detection kit was purchased from Roche (Cell Death Detection Kit; Roche Biochemicals; Mannheim, Germany). LC3A/B monoclonal antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).
Culture of NB4 cells and NRLVMs
Human promyelocytic leukemia NB4 cell line, established in 1991 from a patient suffering from APL having the t(15;17) translocation, was a kind gift from Dr. M. Lanotte (INSERM Unit301, St Louis Hospital, Paris, France) [21]. NB4 cells were collected, washed two times in RPMI1640, counted and resuspended at 500,000 cells/ml in RPMI1640 with 10% fetal bovine serum (FBS). After 24 h cultivation, the cells were sedimented by centrifugation (1500×g for 5 min). NRLVMs were isolated from neonatal rat hearts of 1- to 2-day-old Sprague-Dawley rats. Briefly, the rats were immersed in 75% alcohol and decapitated, and the hearts were then quickly removed and seeded in cold Dulbecco's modified Eagle medium (DMEM). These hearts were cut into small pieces with scissors and digested with 0.25% trypsin solution. The isolated cardiomyocytes were placed in DMEM with 10% FBS and centrifuged, and pellets were resuspended and cultured for 90 min at 37°C. Cardiomyocyte-enriched suspensions were removed from the culture flask and placed in fresh medium. The use of animals complied with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, No. 85–23, revised 1996) and the study protocol was pre-approved by the Experimental Animal Ethics Committee of the Harbin Medical University, China (Animal Experimental Ethical Inspection Protocol, No. 2009104). NRLVMs were pretreated with Rev (5 µM) or Gen (50 µM) for 1 h and then co-incubated with As2O3 (5 µM) [22] for another 24 h. The procedure was the same for NB4 cells, except that a concentration of 2 µM As2O3 was used [23].
Measurement of ROS production
Measurement of intracellular ROS production was based on the oxidation of DCFH-DA to fluorescent 2′,7′-dichlorofluorescin (DCF). Cells were cultured for 12 h followed by incubation with Rev (5 µM) or Gen (50 µM) for 1 h, and then co-incubation with As2O3, or were incubated with As2O3 alone for 12 h. A concentration of 5 µM and 2 µM of As2O3 was used for NRLVMs and NB4 cells, respectively. The cells were then further incubated with 10 µM DCFH-DA at 37°C for 30 min, and then washed twice with serum-free medium and stored in FBS-free medium. Cellular DCF fluorescence intensities were detected by confocal microscopy with excitation and emission spectra of 488 nm and 525 nm, respectively.
Measurement of intracellular GSH
NB4 cells or NRLVMs were seeded in 6-well plate. After the cells grew into 90% confluence, they were treated with Rev+As2O3 or Rev at the indicated concentration. After 24 hours of Rev+As2O3 or Rev exposure, the cells were trypsinized, harvested and centrifuged at 1000×g, for 3 min. Cell pellets were removed to 1.5 mL eppendorf tubes, cleaned twice with cold PBS and resuspended in ice-cold metaphosphoric acid (MPA). After homogenization, the solution was centrifuged at 10,000×g at 4°C for 10 min and then the supernatant was applied to measure levels of GSH according to the manufacturer’s instructions (Bioxytech-GSH 400, OxisResearch, Portland, OR, USA). The assay was carried out in eppendorf tubes and transferred to flat-bottom 96-well plates for absorbance measurement at 400 nm. The pellet from the centrifugation was dissolved in 100 µL of 0.1 M NaOH and the protein concentration was determined by the Bio-Rad microprotein assay in 96-well plate using bovine serum albumin as the standard. The GSH level was expressed as nmol GSH/mg cellular protein.
Measurement of mitochondrial membrane potential (MMP)
JC-1 was applied to explore the effects of Gen and Rev on mitochondrial function by measuring MMP in As2O3-treated cardiomyocytes and NB4 cells. Cells were placed in a 6-well plate and cultured for 12 h at 37°C and then incubated with Rev (5 µM) or Gen (50 µM) for 1 h prior to co-treatment with As2O3, or were incubated with As2O3 alone for another 12 h. A concentration of 5 µM and 2 µM of As2O3 was used for NRLVMs and NB4 cells, respectively. Red emission of the dye represents normal MMP and green fluorescence indicates mitochondria with depolarized MMP. MMP was measured using a confocal laser-scanning microscope (Fluoview-FV300; Olympus, Tokyo, Japan).
Determination of superoxide dismutase (SOD) activity
The activity of the anti-oxidant enzyme SOD in NRLVMs and NB4 cells was detected by using a Total Superoxide Dismutase Assay Kit with WST-1 according to the manufacturer’s protocol. Briefly, cells were exposed to Rev (5 µM) or Gen (50 µM) for 1 h following treatment with As2O3 for another 24 h. A concentration of 5 µM and 2 µM of As2O3 was used for NRLVMs and NB4 cells, respectively. Then, the cell suspension was centrifuged (800×g, 10 min, 4°C), and the cell pellets were ultrasonicated for 15 min (every 15 s with 5-min intervals) at 4°C in cell lysate buffer [RIPA buffer, 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), sodium orthovanadate, sodium fluoride, ethylenediamine tetraacetic acid, and leupeptin]. After the cell-lysed buffer was centrifuged at 2000×g for 15 min, the supernatant was removed. Supernatants, enzyme-working solutions, and WST-1 were prepared and added to a 96-well plate. The mixtures were incubated at 37°C for 20 min, and the absorbance was finally determined at 450 nm using a microplate reader.
Protein extraction and immunoblotting analysis
Protein samples were isolated from NRLVMs and NB4 cells. NRLVMs and NB4 cells were seeded in 6-well plate at 37°C in 5% CO2. After treatment with different types of drugs, the two types of cells were collected from 6-well plate, then the cell suspension was centrifuged (800×g, 10 min, 4°C), and the cell pellets were ultrasonicated for 15 min (every 15 s with 5 min intervals) at 4°C in cell lysate buffer (RIPA buffer, 50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride, EDTA and leupeptin). After cells-lysed buffer was centrifuged at 1000×g for 15 min, the supernatant protein samples were kept for the following experiments. The isolated protein samples were subjected to 15% SDS-polyacrylamide gel electrophoresis, blotted to a nitrocellulose membrane, and then blocked with 5% non-fat milk for 120 min. Next, the membranes were probed with LC3A/B in phosphate-buffered saline (PBS) containing 1% BSA and incubated overnight at 4°C. Thereafter, membranes were washed three times with PBS for 30 min and incubated with secondary antibody (Alexa Fluor; Molecular Probes; Eugene, OR, USA) for 1 h. The bands were acquired using an imaging system (LI-COR Biosciences; Lincoln, NE, USA), and quantified with Odyssey v3.0 software by measuring the band intensity [area×optical density (OD)] in each group using β-actin (anti-β-actin antibody) as an internal control for normalization.
Measurement of cell viability
The cell viability was measured with an MTT reduction assay using a previously described method [24]. Briefly, cells were seeded in serum-free DMEM for 24 h, followed by administration with the indicated concentrations of agents at each time point. After incubation, the cells were quickly washed twice with cold PBS and added to MTT solution (final concentration, 5 mg/mL) for 4 h at 37°C. Then, the supernatant was removed and formazan crystals were dissolved with dimethylsulfoxide (150 µL) for 10 min. The absorbance was measured at 490 nm. Notably, the effect of Rev and As2O3 on the cell viability of NB4 cells was quantitatively assessed by calculating combination index (CI) as described before [25].
TUNEL assay
The cells were treated as described above. DNA fragmentation of the cells was then determined using the TUNEL assay. Briefly, air-dried slides were fixed with 4% paraformaldehyde for 30 min at room temperature, washed three times with PBS, and then permeabilized with 1% Triton X-100 for 4 min at 4°C. Subsequently, a TdT-labeled nucleotide mix was added to each slide and incubated at 37°C for 60 min in the dark. Slides were washed twice with PBS and then counterstained with 10 mg/mL 4,6-diamidino-2-phenylindole (DAPI) for 5 min at 37°C.
Flow cytometric analysis of cell apoptosis
The extent of apoptosis was detected by using annexinV-FITC apoptosis detection kit as described in the manufacturer’s instructions [26]. After NB4 cells or NRLVMs had been treated with Rev+As2O3 or Rev for 24 h, cells were harvested, and carefully washed with PBS for three times. After centrifugation at 1000×g for 5 min, the cell pellets were resuspended in 195 µL annexin V binding buffer and gently mixed by adding another 5 µL annexin V binding buffer. The suspension was then incubated in the dark for 10 min at room temperature. Thereafter, the supernatant was removed by centrifugation at 1000×g for 5 min. After 190 µL of annexin V binding buffer and 10 µL of propidiumiodide (50 mg/mL) were added, the fluorescence of these cells were analyzed by flow cytometry using the FloMax software. The fraction of cell population in different quadrants was analyzed using quadrant statistics. The lower left quadrant indicated normal cells; lower right quadrant represented early apoptotic cells and in the upper right quadrant was late apoptotic cells. The upper left quadrant was necrotic cells.
Results
Co-treatment of Gen/Rev further increased As2O3-induced oxidative stress in NB4 cells but relieved oxidative stress in NRLVMs
Consistent with previous studies [27]–[29], the individual compounds, Rev, Gen, and As2O3, substantially induced endogenous production of ROS in NB4 cells (Figure 1A and C). Mitochondrial malfunction, in conjunction with other factors such as increased metabolic activity and oncogenic stimulation, contributed to the heightened redox status of cancer cells, whereas excessive ROS generation inevitably aggravated tumor cell damage [30]. Significant alteration of MMP clearly indicated drug-induced damage to the mitochondria, the main intrinsic source of ROS, in NB4 cells (Figure 2A and C). Combination of As2O3 and Gen/Rev led to a more dramatic release of ROS from dysfunctional mitochondria than single drug treatment. Combined application of As2O3 and Gen/Rev also caused a remarkable decline in SOD activity (Figure 3A and C). As SOD is one of the main endogenous free radical scavenging enzymes, this finding suggests the continuous accumulation of ROS. Simultaneously reduced GSH level further exacerbated the injuries by excessive cellular oxidative stress (Figure S1A). In contrast to these phenomena observed in NB4 cells, the drug combination treatment in NRLVMs showed neutralized effects on ROS generation, MMP, GSH level, and SOD activity rather than synergistic effects (Figures 1–3 and S1B). Both Rev (5 µM) and Gen (50 µM) obviously mitigated the As2O3-induced increase of ROS and mitochondrial injury in cardiomyocytes, demonstrating cytoprotection against the cardiotoxicity caused by As2O3. In addition, successful reversal of SOD activity to basal levels suggested the restored ability of cardiomyocytes to scavenge ROS.
Co-treatment of 5 µM Rev or 50 µM Gen further increased ROS production in NB4 cells compared to As2O3 alone (A, C) but reduced the ROS level in NRLVMs (B, D). ***p<0.001, As2O3+Rev versus As2O3 or Rev; ***p<0.001, As2O3+Gen versus As2O3 or Gen.
Co-treatment of 5 µM Rev or 50 µM Gen further decreased the MMP in NB4 cells compared to As2O3 alone (A, C) but restored MMP in NRLVMs (B, D). ***p<0.001, As2O3+Rev versus As2O3 or Rev; ***p<0.001, As2O3+Gen versus Gen; **p = 0.005, ***p<0.001, As2O3+Gen versus As2O3.
Co-treatment of 5 µM Rev or 50 µM Gen further decreased the SOD activity in NB4 cells compared to As2O3 alone (A, C) but restored it in NRLVMs (B, D). ***p<0.001, As2O3+Rev versus Rev; *p = 0.023, ***p<0.001, As2O3+Rev versus As2O3; ***p<0.001, As2O3+Gen versus Gen; *p = 0.02, **p = 0.038, As2O3+Gen versus As2O3.
Gen/Rev enhanced As2O3-induced autophagy in NB4 cells and NRLVMs
Increased release of ROS is one of the main endogenous factors for enhancement of cell autophagy [31]. Accordingly, As2O3 obviously increased the expression ratio of LC3 II/LC3 I in NB4 cells following the excessive generation of ROS (Figure 1A and 4A). Our result was in line with a previous study by Qian et al., in which another autophagy marker, Beclin-1, was confirmed to be up-regulated by As2O3 in leukemia cells [32]. Co-treatment with Rev substantially enhanced the effect of As2O3 on autophagy in NB4 cells (Figure 4A). However, to achieve the same effect with Gen, a ten-fold concentration was required (Figure 4C and E). We further confirmed that the autophagy induced by As2O3 was also enhanced by co-treatment with Gen/Rev in NRLVMs (Figure 4B and D). This result is consistent with the cardioprotection that Rev provides via activation of autophagy [33]. As observed in NB4 cells, an equal concentration of Gen failed to enhance autophagy, implying a dosage advantage of Rev relative to Gen (Figure 4F).
Co-treatment of 5 µM Rev or 50 µM Gen further increased the expression ratio of LC3 II/LC3 I in NB4 cells (A, C) and NRLVMs (B, D) compared to As2O3 alone. **p = 0.002, ***p<0.001, As2O3+Rev versus As2O3; **p = 0.004, **p<0.005, As2O3+Gen versus As2O3. No significant difference was found in the expression ratio of LC3 II/LC3 I in NB4 cells (E) and NRLVMs (F) with co-treatment of 5 µM Gen compared to As2O3 alone.
Gen/Rev promoted As2O3-induced apoptosis in NB4 cells but protected against apoptosis in NRLVMs
MTT and TUNEL assays consistently verified that only 2 µM As2O3 was sufficient to substantially induce cell apoptosis of NB4 cells (Figure 5A and 6A), in line with its good therapeutic effect for APL [3]. However, this apoptosis-promoting activity might also contribute to marked cardiac toxicity [16]. Our results indicated that As2O3 substantially decreased the cell viability of NRLVMs and induced cardiomyocyte apoptosis (Figure 5B and 6B). However, addition of Gen/Rev changed the picture. On the one hand, Rev or Gen further exacerbated the apoptotic damage caused by As2O3 in NB4 cells (Figure 5C and 6C), whereas no obvious damage to cell viability and apoptosis was observed in these co-treated cardiomyocytes (Figure 5D and 6D). Additionally, the results of MTT-based CI calculation indicated that Rev act synergistically with As2O3 on inducing cell apoptosis of NB4 cells (Figure S2). This finding was further confirmed by the result of flow cytometry (Figure S3A). Co-administration of 2 µM As2O3 and 5 µM Rev dramatically increased the proportions of early apoptotic cells (27.16%) and late apoptotic cells (34.82%), compared with those of the control NB4 cells (early apoptotic cells, 0.87%; late apoptotic cells, 0.73%). However, 5 µM Rev obviously alleviated As2O3-induced apoptosis in NRLVMs by substantially reducing early apoptotic cells from 20.37% to 12.17% and late apoptotic cells from 7.71% to 1.55% (Figure S3B). The above findings were consistent with the results obtained with respect to ROS generation and LC3 expression in NB4 cells and NRLVMs (Figures 1–4).
Co-treatment of 5 µM Rev or 50 µM Gen further decreased the cell viability of NB4 cells (A, C) but reversed the cell viability of NRLVMs (B, D). ***p<0.001, As2O3+Rev versus Rev or As2O3; ***p<0.001, As2O3+Gen versus Gen; **p = 0.002, ***p<0.001, As2O3+Gen versus As2O3.
Co-treatment of 5 µM Rev or 50 µM Gen further aggravated the As2O3-induced apoptosis of NB4 cells (A, C) but reversed that of NRLVMs (B, D). ***p<0.001, As2O3+Rev versus Rev; ***p = 0.001, ***p<0.001, As2O3+Rev versus As2O3; ***p = 0.001, As2O3+Gen versus Gen; **p = 0.002, ***p<0.001, As2O3+Gen versus As2O3.
Discussion
The outstanding benefit of As2O3 treatment for APL is due to its ability to specifically initiate the degradation of PML/RAR alpha, a core driving oncoprotein of APL [34]. Non-specific actions of As2O3, such as increasing ROS production, also greatly contribute to the mechanism by which APL can be cured with As2O3 [35]. However, as with many drugs, there is another side to these beneficial effects. The excessively amplified ROS generation flux induced by As2O3 inevitably leads to above-threshold toxicity levels in normal cells. Cardiomyocytes are likely to bear the brunt of this toxicity due to enrichment of mitochondria and their particular susceptibility to oxidative stress injury [13]. This has been validated experimentally [9]–[12] and confirmed by a plethora of clinical drug toxicity event reports [5]–[8]. In this study, combinations of As2O3 and the natural antioxidants Gen/Rev were investigated in vitro for the first time to explore their potential for treating APL without inducing cardiotoxicity.
Because of its multiple phenolic hydroxyl groups, the natural product Rev shows strong cytoprotective capacity against ROS generated by different inducers in non-tumor cells [36], which was confirmed in the present study. Rev successfully reversed the As2O3-induced ROS outbreak in NRLVMs. An equivalent effect was achieved with another natural antioxidant, Gen, but at a ten-fold concentration. Interestingly, we found that Rev and Gen played the role of accomplice to As2O3 in NB4 cells by exacerbating intracellular oxidative stress instead of adversary by extinguishing the ROS outbreak. Tumor cells employ a different mechanism to that of non-tumor cells for regulating mitochondrial functions [37], [38], which eventually leads to disparate effectsof the same drug in tumor cells relative to non-tumor cells. Accordingly, in this study, we validated that both Rev and Gen could exacerbate As2O3-induced mitochondrial damage in the NB4 cells, but mitigated the mitochondrial injury caused by As2O3 in cardiomyocytes, in agreement with previous studies [28], [29], [37], [38]. In addition, our experiments demonstrated that Gen/Rev further reduced SOD activity and deteriorated the intracellular ROS environment of NB4 cells by shifting the balance between ROS scavenging factors and ROS release factors. Ultimately, Gen/Rev might accelerate the As2O3-mediated degradation of PML/RARA oncoprotein via maintaining a high level of intracellular ROS, as proposed by Jeanne et al. [35]. This potential mechanism is reasonable to explain the synergistic proapoptotic effect observed by the combination of As2O3 and Gen/Rev.
While significantly relieving the oxidative injury caused by As2O3, 5 µM Rev was still able to enhance the autophagic flux of NRLVMs, indicating ROS-independent activation of autophagy. This role is likely the main contributor to Rev’s myocardial protection, as revealed in previous studies [39], [40]. Although there is currently no consensus as to whether activation or inhibition intervention of autophagy in APL is recommended [41], a study by Qian et al. strongly demonstrated that obvious enhancement of autophagy was indeed associated with the As2O3-mediated cell death of leukemia cells [32]. The results of our study further verified this finding, as autophagic cell death was implicated in the mechanisms by which As2O3 counteracts cell proliferation and promotes apoptosis of NB4 cells; Gen/Rev strengthened its pro-apoptotic effect via further elevating the level of autophagy.
In conclusion, we presented here in vitro evidence for synergistic antileukemic action of As2O3 and Rev from multiple aspects including oxidative stress, autophagy, and apoptosis. Meanwhile, the cardioprotective potential of Rev was also validated against As2O3-induced cardiomyocytes injury. Compared with Gen, the lower effective concentration of Rev indicates its potential as a rational drug candidate for APL treatment in combination with As2O3. Our findings provide a novel therapeutic possibility for APL with enhanced efficiency and reduced toxicity. Further functional experiments in vivo are required to validate our findings.
Supporting Information
Figure S1.
Co-treatment of As2O3 and Rev on total GSH level in NB4 cells and NRLVMs (n = 6). Co-treatment of 5 µM Rev further decreased the GSH level in NB4 cells (A) but reversed that of NRLVMs (B). ***p<0.001 or p = 0.001, versus As2O3+Rev.
https://doi.org/10.1371/journal.pone.0105890.s001
(TIF)
Figure S2.
Result of CI calculation of the combinations of As2O3 and Rev on the cell viability of NB4 cells (n = 6). A. Effect of As2O3+Rev combinations of different concentrations on the cell viability of NB4 cells. B. CI values of As2O3+Rev combinations at different concentrations. A CI value of less than 1 means synergistic action by As2O3 and Rev.
https://doi.org/10.1371/journal.pone.0105890.s002
(TIF)
Figure S3.
Result of flow cytometric analysis of cell apoptosis in NB4 cells and NRLVMs. Co-treatment of 5 µM Rev and 2 µM As2O3 synergistically promoted early and late apoptosis instead of necrosis in NB4 cells (A). Addition of 5 µM Rev markedly relieved cardiomyocyte apoptosis that was induced by 5 µM As2O3 (B).
https://doi.org/10.1371/journal.pone.0105890.s003
(TIF)
Author Contributions
Conceived and designed the experiments: YF WZ. Performed the experiments: YF MC JM LY YT LW KF. Analyzed the data: YF WZ. Contributed reagents/materials/analysis tools: YF WZ. Wrote the paper: YF WZ.
References
- 1. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341–1348.
- 2. Fox E, Razzouk BI, Widemann BC, Xiao S, O’Brien M, et al. (2008) Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111: 566–573.
- 3. Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A (2011) Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis 3: e2011056.
- 4. Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21: 3609–3615.
- 5. Drolet B, Simard C, Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109: 26–29.
- 6. Mumford JL, Wu K, Xia Y, Kwok R, Yang Z, et al. (2007) Chronic Arsenic Exposure and Cardiac Repolarization Abnormalities with QT Interval Prolongation in a Population-based Study. Environ Health Perspect 115: 690–694.
- 7. Vizzardi E, Zanini G, Antonioli E, D'Aloia A, Raddino R, et al. (2008) QT prolongation: a case of arsenical pericardial and pleural effusion. Cardiovasc Toxicol 8: 41–44.
- 8. Ducas RA, Seftel MD, Ducas J, Seifer C (2011) Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. J R Coll Physicians Edinb 41: 117–118.
- 9. Li Y, Sun X, Wang L, Zhou Z, Kang YJ (2002) Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol 2: 63–73.
- 10. Hirano S, Cui X, Li S, Kanno S, Kobayashi Y, et al. (2003) Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch Toxicol 77: 305–312.
- 11. Hwang JT, Kwon DY, Park OJ, Kim MS (2008) Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2: 323–326.
- 12. Manna P, Sinha M, Sil PC (2008) Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Arch Toxicol 82: 137–149.
- 13. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, et al. (2001) Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 89: 279–286.
- 14. Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, et al. (2011) Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des 17: 2113–2129.
- 15. Zhang W, Guo C, Gao R, Ge M, Zhu Y, et al. (2013) The Protective Role of Resveratrol against Arsenic Trioxide-Induced Cardiotoxicity. Evid Based Complement Alternat Med 2013: 407839.
- 16. Fan Y, Wang C, Zhang Y, Hang P, Liu Y, et al. (2013) Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis. Cell Physiol Biochem 31: 80–91.
- 17. Hollman PC, Katan MB (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 37: 937–942.
- 18. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546: 121–165.
- 19. Sun W, Wang W, Kim J, Keng P, Yang S, et al. (2008) Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 614: 179–186.
- 20. Lee J, Giordano S, Zhang J (2012) Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441: 523–540.
- 21. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080–1086.
- 22. Chu W, Li C, Qu X, Zhao D, Wang X, et al. (2012) Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome. Cardiovasc Res 96: 90–98.
- 23. Ghaffari SH, Bashash D, Dizaji MZ, Ghavamzadeh A, Alimoghaddam K (2012) Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol 33: 157–172.
- 24. Park SY, Sohn UD (2011) Inhibitory effect of rosiglitazone on the acid-induced intracellular generation of hydrogen peroxide in cultured feline esophageal epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 383: 191–201.
- 25. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621–81.
- 26. Jiang S, Zu Y, Fu Y, Zhang Y, Efferth T (2008) Activation of the mitochondria driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol 33: 103–111.
- 27. Gao F, Yi J, Yuan JQ, Shi GY, Tang XM (2004) The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res 14: 81–85.
- 28. Heiss EH, Schilder YD, Dirsch VM (2007) Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem 282: 26759–26766.
- 29. Ullah MF, Ahmad A, Zubair H, Khan HY, Wang Z, et al. (2011) Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. Mol Nutr Food Res 55: 553–559.
- 30. Liou GY, Storz P (2010) Reactive oxygen species in cancer. Free Radic Res 44: 479–496.
- 31. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, et al. (2007) Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26: 1749–60.
- 32. Qian W, Liu J, Jin J, Ni W, Xu W (2007) Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 31: 329–339.
- 33. Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, et al. (2013) Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol 182: 701–713.
- 34. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, et al. (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240–243.
- 35. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, et al. (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18: 88–98.
- 36. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, et al. (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309: 1017–1026.
- 37. Sun W, Wang W, Kim J, Keng P, Yang S, et al. (2008) Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 614: 179–186.
- 38. Nadal-Serrano M, Pons DG, Sastre-Serra J, Blanquer-Rosselló Mdel M, Roca P, et al. (2013) Genistein modulates oxidative stress in breast cancer cell lines according to ERα/ERβ ratio: effects on mitochondrial functionality, sirtuins, uncoupling protein 2 and antioxidant enzymes. Int J Biochem Cell Biol 45: 2045–2051.
- 39. Xuan W, Wu B, Chen C, Chen B, Zhang W, et al. (2012) Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*. Crit Care Med 40: 3026–3033.
- 40. Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, et al. (2013) Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol. 182: 701–713.
- 41. Nencioni A, Cea M, Montecucco F, Longo VD, Patrone F, et al. (2013) Autophagy in blood cancers: biological role and therapeutic implications. Haematologica 98: 1335–1343.